Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Alpha-GPC (L-alpha-glycerylphosphorylcholine / choline alfoscerate) and Sunifiram — mechanism, dosing, side effects, legal status, and pricing.
Alpha-GPC is a non-peptide choline-containing phospholipid derivative that serves as an acetylcholine precursor. It is not FDA-approved in the United States, where it is sold as an unregulated dietary supplement and nootropic ingredient. The compound is marketed as a prescription drug in some countries (e.g., Italy as Gliatilin) for cognitive and vascular disorders, though current regulatory approval status has not been confirmed against primary agency databases. Alpha-GPC is not identified as a WADA-prohibited substance in secondary sources.
Sunifiram (DM-235) is a synthetic non-peptide piperazine derivative marketed online as an 'ampakine-like' cognitive enhancer. Despite common branding, primary research shows it acts indirectly via the glycine-binding site of the NMDA receptor to potentiate AMPA-receptor-mediated transmission, not as a direct AMPA agonist. No human clinical trials or toxicology studies have been conducted, and sunifiram is not approved for any human or veterinary use worldwide. It is sold on the gray market without regulatory vetting.
Alpha-GPC (L-alpha-glycerylphosphorylcholine / choline alfoscerate)
Sunifiram
Category
Legal Status
Mechanism
Dose Range
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Alpha-GPC (L-alpha-glycerylphosphorylcholine / choline alfoscerate)
Sunifiram
COA corpus from Disclosed Labs — independently tested batches only.
Alpha-GPC (L-alpha-glycerylphosphorylcholine / choline alfoscerate)
No COA data yet.
Submit testing data →Sunifiram
1
COAs
99.5%
Avg purity
1
Labs
Human data: A 12-week randomized controlled trial in 100 subjects with amnestic mild cognitive impairment found 600 mg/day improved ADAS-cog scores by 2.34 points versus placebo with no serious adverse events. A single-blind RCT in 39 healthy volunteers showed 400 mg/day for 2 weeks increased self-reported motivation versus placebo. A small crossover study in 7 resistance-trained men (published only as a conference-supplement abstract) reported a single acute 600 mg dose increased post-exercise growth hormone and peak bench-press force versus placebo. A large retrospective Korean cohort study (n=12,008,977 adults ≥50) found chronic alpha-GPC use associated with elevated 10-year stroke risk (total stroke adjusted HR 1.43, ischemic stroke aHR 1.34) in a dose-dependent pattern. Preclinical: Rat studies showed increased hippocampal acetylcholine release, modulation of choline acetyltransferase/acetylcholinesterase activity in aged rats, attenuation of age-related brain structural changes, and increased hippocampal neurogenesis in seizure models.
Key references
No human data exist. In olfactory-bulbectomized mice given oral sunifiram 0.01–1.0 mg/kg daily for 7–12 days, spatial reference memory (Y-maze) and short-term recognition memory (novel object recognition) improved, and impaired hippocampal CA1 long-term potentiation was restored via NMDAR-glycine-site-dependent CaMKII/PKC signaling (blocked by gavestinel). In mouse hippocampal slices, sunifiram (1–1000 nM, peaking at 10 nM with a bell-shaped dose-response) potentiated CA1 LTP via the glycine-site/PKCα/CaMKII pathway. In passive-avoidance models, sunifiram reversed amnesia in mice and rats at doses roughly four orders of magnitude lower than piracetam. No toxicology studies or human clinical trials have been conducted as of 2016.
Alpha-GPC (L-alpha-glycerylphosphorylcholine / choline alfoscerate) and Sunifiram are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Route
Frequency
Dosing Notes
Side Effects
Contraindications
Lab Testing
Key references
Disclosed Labs